Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches

Recent publication by our co-founder and chairman, Jay Short, that discussing the mechanism he developed that enables our product candidates to be conditionally active around cancer cells.

View PDF

View LinkedIn post